Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Avanir Neurodex NDA Delayed By FDA Request For Additional Analyses

This article was originally published in The Pink Sheet Daily

Executive Summary

Agency requested new summary analyses "to better support the new electronic data submission guidelines," the company says.

You may also be interested in...



No Laughing Matter: Avanir Resubmits Neurodex NDA

The firm is requesting priority review for involuntary emotional expression disorder.

No Laughing Matter: Avanir Resubmits Neurodex NDA

The firm is requesting priority review for involuntary emotional expression disorder.

FDA Extends Agilect User Fee Deadline Due To “Technical Error”

FDA is extending the user fee deadline for Teva's Parkinson's disease agent Agilect (rasagiline) by three months following the firm's submission of additional data to clarify a "technical error.

Related Content

Topics

UsernamePublicRestriction

Register

PS062928

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel